Corbus Pharmaceuticals Holdings, Inc.

Listed Company

CRBPCIK 0001595097NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-78.54M

Total Assets

$168.19M

Equity

$147.50M

Shares Out

17.74M

Op. Cash Flow

$-64.49M

Business

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company that discovers and develops therapeutic drug candidates targeting well-understood biological pathways. Its main product candidates include CRB-701, a next‑generation Nectin‑4 antibody‑drug conjugate with an MMAE payload; CRB‑601, an anti‑αvβ8 integrin monoclonal antibody that blocks TGFβ activation; and CRB‑913, a peripherally restricted CB1 receptor inverse agonist for obesity. The company organizes around preclinical research, clinical development and regulatory activities, intellectual property management, and licensing/partnering. It conducts clinical trials and has licensed commercialization rights and clinical activities across the U.S., Canada, the European Union, the U.K., Australia and China while relying on third‑party contract manufacturers and partners for supply and distribution.

Summary from filing dated 2025-03-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	70	32	31	16	36
General and administrative	15	16	14	19	20
Total operating expenses	85	49	45	40	57
Operating loss	−85	−49	−45	−40	−56
Interest and investment income, net	6	6	2	—	—
Interest expense	0	−2	−4	—	—
Other income, net	1	4	3	−48,773	12
Total other income, net	7	9	474,000	−3	10
Net loss	−79	−40	−45	−42	−46
Net loss per share, basic	−5.9	−3.68	−10.31	−10.15	−11.15
Net loss per share of common stock diluted	−5.9	−3.68	−10.31	−10.15	−11.15
Weighted average number of common shares outstanding, basic	13	11	4	4	4
Weighted average number of common shares outstanding, diluted	13	11	4	4	4
Net Income (Loss)	−79	−40	−45	−42	−46
Change in unrealized (loss) gain on marketable debt securities	−88,000	36,000	125,000	−63,647	−62,445
Total other comprehensive (loss) income	−88,000	36,000	125,000	−63,647	−62,445
Total comprehensive loss	−79	−40	−44	−42	−46

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	28	17	14	17	25
Investments	135	132	7	42	73
Restricted cash	670,000	285,000	192,000	192,475	192,475
Prepaid expenses and other current assets	3	4	2	791,616	2
Total current assets	167	153	24	60	100
Restricted cash	0	385,000	478,000	477,425	477,425
Property and equipment, net	159,000	385,000	973,000	2	2
Operating lease right-of-use assets	1	2	3	4	5
Total assets	168	156	28	66	108
Accounts payable	2	5	3	2	2
Accrued expenses	17	5	11	6	10
Operating lease liabilities, current	2	2	1	1	1
Total current liabilities	21	12	32	13	17
Operating lease liabilities, noncurrent	0	2	3	5	6
Total liabilities	21	13	35	33	39
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized,17,611,511 and 12,179,482 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	2,000	1,000	0	417	416
Additional paid-in capital	703	619	430	425	419
Accumulated deficit	−555	−477	−437	−392	−350
Accumulated other comprehensive loss	−53,000	35,000	−1,000	−126,092	−62,445
Total stockholders equity	148	142	−7	33	69
Total liabilities and stockholders equity	168	156	28	66	108

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	6	6	3	6	9
Depreciation expense	233,000	588,000	641,000	762,995	999,817
Net amortization of premiums and discounts on investments	−1	−3	−506,000	124,875	—
Amortization of debt discount	0	396,000	824,000	742,478	700,613
Other	−229,000	189,000	−19,000	—	—
Decrease (increase) in prepaid expenses and other current assets	634,000	−1	−1	—	—
Decrease in other assets	0	212,000	−57,000	—	—
Decrease in operating lease right-of-use asset	1	930,000	—	—	—
Decrease in other long-term liabilities	0	−44,000	22,000	—	—
(Decrease) increase in accounts payable	−2	2	1	−256,835	−6
Increase (decrease) in accrued expenses	11	−6	5	−4	−12
Decrease in operating lease liabilities	−2	−1	−1	−1	−1
Net cash used in operating activities	−64	−42	−36	−38	−48
Purchases of property and equipment	−7,000	0	0	−13,449	−54,172
Purchases of investments	−163	−181	−34	−86	−87
Proceeds from sales and maturities of investments	161	59	70	116	14
Net cash used in investing activities	−2	−121	36	30	−73
Proceeds from issuance of common stock and pre-funded warrants, net	77	182	53,000	—	63
Repayment of short-term borrowings	0	−301,000	−426,000	−866,865	−926,595
Repayment of long-term borrowings	0	−15	−3	−2	—
Net cash provided by (used in) financing activities	77	167	−3	−533,615	61
Net increase in cash, cash equivalents, and restricted cash	11	3	−3	−8	−61
Cash paid during the period for interest	0	3	3	2	2
Write-off of fully depreciated property and equipment	0	71,000	178,000	0	544,752
Common stock issuance costs not yet paid	62,000	75,000	0	—	—
Issuance of common stock for conversion of convertible debt	0	1	875,000	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro